

BIBLIOGRAPHY

Molecular Immunology Lab



The Thrombosis Research Institute (TRI) has published over 60 papers reporting on the results of our laboratory research over the last 30 years.



TRI has been at the centre of the global understanding of thrombosis for several decades, producing the highest calibre research into the condition.

Our laboratory research projects are concerned with the fundamental mechanisms involved in blood coagulation, inflammation and atherogenesis, as well as how these processes are regulated. Our multi-disciplinary approach allows us to address these investigations at a molecular level.

The published outputs of our laboratory research studies from 1993 to date are summarised in this document.

Updated May 2023

Manuscripts

1. Lu X. **Structure and Function of Ligand CX3CL1 and its Receptor CX3CR1 in Cancer.** *Curr Med Chem.* 2022;29(41):6228-6246. doi: 10.2174/0929867329666220629140540.
2. Lu X. **Structure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer.** *Curr Med Chem.* 2022;29(11):1851-1865. doi: 10.2174/0929867328666210806120904.
3. Lu X. **OX40 and OX40L Interaction in Cancer.** *Curr Med Chem.* 2021;28(28):5659-5673. doi: 10.2174/0929867328666201229123151.
4. Chen D, Li K, Festenstein S, Karegli J, Wilkinson H, Leonard H, Wei LL, Ma N, Xia M, Tam H, Wang JA, Xu Q, McVey JH, Smith RAG, Dorling A. **Regression of Atherosclerosis in ApoE^{-/-} Mice Via Modulation of Monocyte Recruitment and Phenotype, Induced by Weekly Dosing of a Novel "Cytotoxic" Anti-Thrombin Without Prolonged Anticoagulation.** *J Am Heart Assoc.* 2020 Jul 7;9(13):e014811. doi: 10.1161/JAHA.119.014811.
5. Lu X. **The role of large neutral amino acid transporter (LAT1) in cancer.** *Curr Cancer Drug Targets.* 2019 Aug 2. doi: 10.2174/1568009619666190802135714.
6. Lu X. **Structure and function of angiotensin-like protein 3 (ANGPTL3) in atherosclerosis.** *Curr Med Chem.* 2019 Jun 21. doi: 10.2174/0929867326666190621120523.
7. Lu X. **Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.** *Curr Drug Targets.* 2019; 20(10):1029-1040.
8. Lantos I, Endr sz V, Virok D.P, Szabo A, Lu X, Mosolyg  T, and Burian K. **Chlamydia pneumoniae Infection Exacerbates Atherosclerosis in ApoB100only/LDLR^{-/-} Mouse Strain.** *Biomed Res Int.* 2018 Mar 25; 2018:8325915.
9. Thota LN, Ponnusamy T, Lu X, Mundkur L. **Long-Term Efficacy and Safety of Immunomodulatory Therapy for Atherosclerosis.** *Cardiovasc Drugs Ther.* 2019 Aug; 33(4):385-398.
10. Jing C, Guo M, Bao X, Li T, Lin J, Lu X, Wang W. **Pitavastatin up-regulates eNOS production by suppressing miR-155 expression in lipopolysaccharide-stimulated human umbilical vein endothelial cells.** *Cardiovasc Ther.* 2017 Oct; 35(5).
11. Lu X. **The role of exosomes and exosome-derived microRNAs in atherosclerosis.** *Curr Pharm Des.* 2017; 23(40):6182-6193.
12. Lu X. **Impact of IL-12 in cancer.** *Curr Cancer Drug Targets.* 2017; 17(8):682-697.
13. Lu X. **The impact of IL-17 in atherosclerosis.** *Curr Med Chem.* 2017; 24(21):2345-2358.
14. Thota LN, Ponnusamy T, Philip S, Lu X, Mundkur L. **Immune regulation by oral tolerance induces alternate activation of macrophages and reduces markers of plaque destabilization in Apobtm2Sgy/Ldlrtm1Her/J mice.** *Sci Rep.* 2017 Jun 21; 7(1):3997.
15. Lu X. **Impact of Macrophages in Atherosclerosis.** *Curr Med Chem.* 2016; 23(18):1926-37.
16. Deshpande V, Krishnan R, Philip S, Faludi I, Ponnusamy T, Thota LN, Endresz V, Lu X, Kakkar VV, Mundkur L. **Oral administration of recombinant Mycobacterium smegmatis expressing a tri-peptide construct derived from endogenous and microbial antigens prevents atherosclerosis in ApoE^{-/-} mice.** *Cardiovasc Ther.* 2016 Oct; 34(5):314-24.

17. Lin J, Kakkar V, Lu X. **Essential Roles of Toll-Like Receptors in Atherosclerosis**. *Curr Med Chem*. 2016; 23(5):431-54.
18. Philip S, Ponnusamy T, Rao LN, Biradar S, Kumar R, Deshpande V, Lu X, Kakkar VV, Mundkur LA. **Regulating Inflammatory Immune Response to Atherogenic Antigens Prevents Development and Progression of Atherosclerosis in New Zealand White Rabbits**. *Can J Cardiol*. 2016 Aug; 32(8):1008.e1-1008.e10.
19. Lin J, Kakkar V, Lu X. **The role of interleukin 35 in atherosclerosis**. *Curr Pharm Des*. 2015; 21(35):5151-9.
20. Chen D, Xia M, Hayford C, Tham el-L, Semik V, Hurst S, Chen Y, Tam HH, Pan J, Wang Y, Tan X, Lan HY, Shen H, Kakkar VV, Xu Q, McVey JH, Dorling A. **Expression of human tissue factor pathway inhibitor on vascular smooth muscle cells inhibits secretion of macrophage migration inhibitory factor and attenuates atherosclerosis in ApoE^{-/-} mice**. *Circulation*. 2015 Apr 14;131(15):1350-60
21. Xia M, Chen D, Endresz V, Lantos I, Szabo A, Kakkar V, Lu X. **Modulation of recombinant antigenic constructs containing multi-epitopes towards effective reduction of atherosclerotic lesion in B6;129S-Ldlr(tm1Her)ApoB(tm2Sgy)/J mice**. *PLoS One*. 2015 Apr 1;10(4):e0123393
22. Mundkur L, Ponnusamy T, Philip S, Rao LN, Biradar S, Deshpande V, Kumar R, Lu X, Kakkar VV. **Oral dosing with multi-antigenic construct induces atheroprotective immune tolerance to individual peptides in mice**. *Int J Cardiol*. 2014 Aug 1; 175(2):340-51.
23. Lin J, Kakkar V, Lu X. **Impact of MCP-1 in atherosclerosis**. *Curr Pharm Des*. 2014; 20(28):4580-8.
24. Lin J, Kakkar V, Lu X. **Impact of matrix metalloproteinases on atherosclerosis**. *Curr Drug Targets*. 2014 Apr; 15(4):442-53.
25. Lu X and Kakkar V. **Inflammasome and atherogenesis**. *Curr Pharm Des*. 2014; 20(1):108-24.
26. Lu X, Kakkar V. **The roles of microRNAs in atherosclerosis**. *Curr Med Chem*. 2014; 21(13):1531-43.
27. Xia M, Chen D, Endresz V, Faludi I, Szabo A, Gonczol E, Kakkar V, Lu X. **Immunization of Chlamydia pneumoniae (Cpn)-infected ApoB(tm2Sgy)Ldlr(tm1Her)/J mice with a combined peptide of Cpn significantly reduces atherosclerotic lesion development**. *PLoS One*. 2013 Dec 13; 8(12):e81056.
28. Chen Y, Scully M, Dawson G, Goodwin C, Xia M, Lu X, Kakkar A. **Perturbation of the heparin/heparin-sulfate interactome of human breast cancer cells modulates pro-tumourigenic effects associated with PI3K/Akt and MAPK/ERK signalling**. *Thromb Haemost*. 2013 Jun; 109(6):1148-57.
29. Mundkur L, Mukhopadhyay R, Samson S, Varma M, Kale D, Chen D, Shivaprasad S, Sivanandan H, Soman V, Lu X, Kakkar VV. **Mucosal tolerance to a combination of ApoB and HSP60 peptides controls plaque progression and stabilizes vulnerable plaque in ApoB(tm2Sgy)Ldlr(tm1Her)/J mice**. *PLoS One*. 2013; 8(3):e58364.
30. Mundkur LA, Varma M, Shivanandan H, Krishna D, Kumar K, Lu X, Kakkar VV. **Activation of inflammatory cells and cytokines by peptide epitopes in vitro: a simple in-vitro screening assay for prioritizing them for in-vivo studies**. *Inflamm Res*. 2013 May; 62(5):471-81.
31. Mundkur L, Mukhopadhyay R, Deshpande V, Samson S, Tarate S, Varma M, Shivaprasad S, Lu X and Kakkar V. **Comparison of Oral Tolerance to ApoB and HSP60 Peptides in Preventing Atherosclerosis Lesion Formation in ApoB48⁻/Ldlr⁻ Mice**. *Journal of Vaccines*. 2013. www.hindawi.com/journals/jvac/
32. Lu X, Xia M, Endresz V, Faludi I, Szabo A, Gonczol E, Mundkur L, Chen D, Kakkar V. **Impact of multiple antigenic epitopes from ApoB100, hHSP60 and Chlamydia pneumoniae on atherosclerotic lesion development in ApoB(tm2Sgy)Ldlr(tm1Her)J mice**. *Atherosclerosis*. 2012 Nov; 225(1):56-68.

33. Lu X, Xia M, Endresz V, Faludi I, Mundkur L, Gonczol E, Chen D, Kakkar VV. **Immunization with a combination of 2 peptides derived from the C5a receptor significantly reduces early atherosclerotic lesion in Ldlr(tm1Her) Apob(tm2Sgy) J mice.** *Arterioscler Thromb Vasc Biol.* 2012 Oct; 32(10):2358-71.
34. Lu X et al. **The role of T-helper cells in atherosclerosis.** *Cardiovasc Hematol Agents Med Chem.* 2011 Jan; 9(1):25-41., 2011; 9:25-41.
35. Lu D, Scully M, Kakkar V, Lu X. **ADAM-15 disintegrin-like domain structure, and function.** *Toxins (Basel).* 2010 Oct; 2(10):2411-27.
36. Lu X et al. **Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early atherosclerotic lesion in Apobtm2SgyLdlrtm1Her/J mice.** *Atherosclerosis.* 2010 Oct; 212(2):472-80. doi: 10.1016/j.atherosclerosis.2010.06.007. Epub 2010 Jun 11.
37. Lu X et al. **The role of heat shock protein (HSP) in atherosclerosis: Pathophysiology and clinical opportunities.** *Curr Med Chem.* 2010; 17(10):957-73.
38. Pei Y, Wang J, Wu K, Xuan X and Lu X. **Ionic liquid-based aqueous two-phase extraction of selected proteins.** *Separation and Purification Technology,* 2009, 64: 288-295.
39. Faludi I, Burian K, Csanadi A, Miczak A, Lu X, Kakkar VV, Gonczol E, Endresz V. **Adjuvant modulation of the immune response of mice against the LcrE protein of Chlamydomphila pneumoniae.** *Int J Med Microbiol. Int J Med Microbiol.* 2009 Nov; 299(7):520-8.
40. Lu X et al. **The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy.** *Perspect Medicin Chem.* 2008 Apr 10; 2:57-73.
41. Lu X et al. **The role of integrin-mediated cell adhesion in atherosclerosis: pathophysiology and clinical opportunities.** *Curr Pharm Des.* 2008;14(22):2140-58
42. Lu X et al. **ADAM proteins - therapeutic potential in cancer.** *Curr Cancer Drug Targets.* 2008 Dec; 8(8):720-32.
43. Lu X et al. **Structure-activity relationship studies on ADAM protein-integrin interactions.** *Cardiovasc Hematol Agents Med Chem.* 2007 Jan; 5(1):29-42.
44. Lu D, Xie S, Sukkar MB, Lu X, Scully MF, Chung KF. **Inhibition of airway smooth muscle adhesion and migration by the disintegrin domain of ADAM-15.** *Am J Respir Cell Mol Biol.* 2007 Oct; 37(4):494-500.
45. Lu D, Chung KF, Xia M, Lu X, Scully M, Kakkar V. **Integrin binding characteristics of the disintegrin-like domain of ADAM-15.** *Thromb Haemost.* 2006 Nov; 96(5):642-51.
46. Lu X et al. **The effect of the single substitution of arginine within the RGD tripeptide motif of a modified neurotoxin dendroaspin on its activity of platelet aggregation and cell adhesion.** *Cell Commun Adhes.* 2006 May-Jun; 13(3):171-83.
47. Lu X et al. **Integrins in drug targeting-RGD templates in toxins.** *Curr Pharm Des.* 2006; 12(22):2749-69.
48. Lu X et al. **Snake venom metalloproteinase containing a disintegrin-like domain, its structure-activity relationships at interacting with integrins.** *Curr Med Chem Cardiovasc Hematol Agents.* 2005 Jul; 3(3):249-60.
49. Lu X, et al. **Modulation of integrin-binding selectivity by mutation within the RGD-loop of snake venom proteins: a novel drug development approach.** *Curr Med Chem Cardiovasc Hematol Agents.* 2003 Jun; 1(2):189-96.

50. Wattam B, Shang D, Rahman S, Egglezou S, Scully M, Kakkar V, Lu X. **Arg-Tyr-Asp (RYD) and Arg-Cys-Asp (RCD) motifs in dendroaspin promote selective inhibition of beta1 and beta3 integrins.** *Biochem J.* 2001 May 15; 356(Pt 1):11-7.
51. Lu X et al. **Evaluation of the role of proline residues flanking the RGD motif of dendroaspin, an inhibitor of platelet aggregation and cell adhesion.** *Biochem J.* 2001 May 1; 355(Pt 3):633-8.
52. Rahman S, Flynn G, Aitken A, Patel Y, Hussain F, Lu X, Loftus JC, French D, Wijelath E, Strand K, Savidge GF. **Differential recognition of snake venom proteins expressing specific Arg-Gly-Asp (RGD) sequence motifs by wild-type and variant integrin alphaIIb beta3: further evidence for distinct sites of RGD ligand recognition exhibiting negative allostery.** *Biochem J.* 2000 Feb 1; 345 Pt 3:701-9.
53. Smith KJ, Jaseja M, Lu X, Williams JA, Hyde EI, Trayer IP. **Three-dimensional structure of the RGD-containing snake toxin albolabrin in solution, based on 1H NMR spectroscopy and simulated annealing calculations.** *Int J Pept Protein Res.* 1996 Sep; 48(3):220-8.
54. Lu X et al. **Substitutions of proline 42 to alanine and methionine 46 to asparagine around the RGD domain of the neurotoxin dendroaspin alter its preferential antagonism to that resembling the disintegrin elegantin.** *J Biol Chem.* 1996 Jan 5; 271(1):289-94.
55. Rahman S, Lu X, Kakkar VV, Authi KS. **The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD.** *Biochem J.* 1995 Nov 15; 312 (Pt 1):223-32.
56. Jaseja M, Lu X, Williams JA, Sutcliffe MJ, Kakkar VV, Parslow RA, Hyde EI. **1H-NMR assignments and secondary structure of dendroaspin, a RGD-containing glycoprotein IIb-IIIa (alpha IIb-beta 3) antagonist with a neurotoxin fold.** *Eur J Biochem.* 1994 Dec 15; 226(3):861-8.
57. Lu X et al. **Preferential antagonism of the interactions of the integrin alpha IIb beta 3 with immobilized glycoprotein ligands by snake-venom RGD (Arg-Gly-Asp) proteins. Evidence supporting a functional role for the amino acid residues flanking the tripeptide RGD in determining the inhibitory properties of snake-venom RGD proteins.** *Biochem J.* 1994 Dec 15; 304 (Pt 3):929-36.
58. Sutcliffe MJ, Jaseja M, Hyde EI, Lu X, Williams JA. **Three-dimensional structure of the RGD-containing neurotoxin homologue dendroaspin.** *Nat Struct Biol.* 1994 Nov; 1(11):802-7.
59. Jaseja M, Smith KJ, Lu X, Williams JA, Trayer H, Trayer IP, Hyde EI. **1H-NMR studies and secondary structure of the RGD-containing snake toxin, albolabrin.** *Eur J Biochem.* 1993 Dec 15; 218(3):853-60.
60. Denis C, Williams JA, Lu X, Meyer D, Baruch D. **Solid-phase von Willebrand factor contains a conformationally active RGD motif that mediates endothelial cell adhesion through the alpha v beta three receptor.** *Blood.* 1993 Dec 15; 82(12):3622-30.
61. Lu X et al. **Synthetic RGD peptides derived from the adhesive domains of snake-venom proteins: evaluation as inhibitors of platelet aggregation.** *Biochem J.* 1993 Nov 15; 296 (Pt 1):21-4.